Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin. 

Secukinumab delivers better QoL improvement in psoriasis than etanercept

2 months ago

Quality-of-life (QoL) improvements in patients with psoriasis are faster and greater with secukinumab than etanercept treatment, according to a recent study.

The analysis centred on the effect of secukinumab treatment on patient-reported health-related QoL as evaluated by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. Researchers compared between secukinumab and etanercept the proportion of participants (n=1,470) achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response and sustained DLQI score 0/1 response up to week 52.

Of the participants, 1,144 received secukinumab and 326 etanercept. Patients in the secukinumab group had significantly higher DLQI score 0/1 response rates than those in the etanercept group at week 24. A significantly shorter median time to DLQI score 0/1 response was seen in secukinumab vs etanercept (12 vs 24 weeks; p<0.01).

The DLQI score 0/1 response was achieved by majority of secukinumab-treated patients at week 24. This was sustained through week 52, along with a 90- to 100-percent decrease in the Psoriasis Area and Severity Index total score response.

The study was limited by the insufficient placebo comparisons during the maintenance period due to rerandomization at week 12, according to researchers.

Findings from a prior research showed that patients receiving secukinumab have greater improvements and more effective relief from psoriasis impact on daily activities and personal relationships than those receiving etanercept. [J Dermatolog Treat 2016;21:1-6]

“Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment,” researchers said.

Editor's Recommendations
Most Read Articles
6 months ago
An early and proper therapeutic strategy for acquired cold urticaria (ACU) will only be possible by knowing the clinical predictors of the disease evolution and the clinical features of ACU phenotypes, according to a recent study.
3 months ago
Atopic dermatitis is a chronic, relapsing, pruritic inflammatory skin disease that affects many children and adults. The goal of this activity is to educate pharmacists on atopic dermatitis and the available pharmacotherapies. 
 
Please click here to access the module. 
10 months ago
Bilastine is a novel second-generation antihistamine that optimizes the treatment of chronic urticaria and allergic rhinitis by effectively balancing its symptom-relieving effects with a unique safety profile. At the recent European Academy of Allergy and Clinical Immunology (EAACI) Congress held in Vienna, Austria, Professor Marcus Maurer of the Charité-Universitätsmedizen, Berlin, Germany, and Associate Professor Marysia Recto of the Asian Hospital and Medical Centre, Muntinlupa City, Philippines, outlined bilastine’s effects on patients with chronic urticaria and allergic rhinitis, while Professor Piotr Kuna from the Medical University of Lodz, Poland, described its unique pharmacokinetics. Their presentations highlighted the unique traits that have ensured that bilastine is the only second-generation antihistamine to meet most of the desired features of an ideal drug described by international guidelines such as ARIA (Allergic Rhinitis and its Impact of Asthma), most notably its rapid onset of action and long-lasting effect, which are achieved without sedation.
Dr. Joseph Delano Fule Robles, 6 months ago

Researchers from the US recently demonstrated synergistic effects of topical calcipotriol and 5-fluorouracil (5-FU) for the treatment of actinic keratosis, a known precursor to squamous cell carcinoma (SCC) of the skin.